Latest News
-

Measuring harmful huntingtin protein in the brain’s bath water
How will we know whether HD-lowering treatments are working? New advancements in the detection of mutant huntingtin.
-

A faulty filter? Blood vessel changes in Huntington's disease
New research reveals blood vessel changes that could contribute to problem in HD
-

Lighting the way: A new biomarker for Huntington’s disease
A new biomarker reveals brain changes in early Huntington's disease.
-

Novel research technique suggests an antioxidant gene protects vulnerable neurons
Researchers use a new technique in an HD mouse to uncover a gene, Gpx6, that is protective to vulnerable neurons.
-

Building a Better Mouse(trap): A New Model of Huntington’s Disease
New mouse model gives insights into Huntington's disease
-

Taking new targets to the bank: the DNA repair protein ‘ATM’ is overactive in Huntington's disease
HD causes the normally helpful protein "ATM" to get a little overzealous. Now we can look for drugs to settle it down
-

2015 Huntington's Disease Therapeutics Conference: Day 3
Day 3 of updates from the annual HD Therapeutics Conference in Palm Springs
-

2015 Huntington's Disease Therapeutics Conference: Day 2
Day 2 of updates from the annual HD Therapeutics Conference in Palm Springs
-

2015 Huntington's Disease Therapeutics Conference: Day 1
Day 1 of updates from the annual HD Therapeutics Conference in Palm Springs
-

Unlocking the Potential of Antibodies as a Therapy for Huntington’s Disease
Antibodies are known for their role in immunity, but researchers repurpose them in many ways. Can they be used in HD?
HDBuzz Trial Tracker
Progress update for NCT06585449 – A Study to Evaluate ALN-HTT02
Additional insights from Phase 2 study results and update on plans for Phase 3 trial for votoplam
Updates from the ongoing placebo-controlled Phase 2/3 FALCON-HD trial
Previously featured
-
Australia Opens The Door for SKY-0515: Skyhawk Seeks Provisional Approval for Its Oral HD Drug
-
The road ahead for uniQure: FDA says more data needed for AMT-130 gene therapy
-
Vico’s Trial Adjusts With Twice-Yearly Dosing, And The U.S. Is Next
-
February 2026: This Month in Huntington’s Disease Research
-
A Window into the Eyes: Using Ocular Biomarkers to Track Progression in Huntington’s Disease
Follow HDBuzz
Sign up to our monthly email summary by entering your email address on our mailing list page.
Suggest an article
Is there something you want us to write about? Tell us about it here. We consider all suggestions but can’t promise to write content about any particular suggestion.
